• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在美国,使用液态人乳强化剂对早产儿的相对成本效益。

Relative cost-effectiveness of using a liquid human milk fortifier in preterm infants in the US.

作者信息

Guest Julian F, Moya Fernando, Sisk Paula M, Hudak Mark L, Kuehn Devon

机构信息

Catalyst Health Economics Consultants, Northwood, Middlesex, UK; Faculty of Life Sciences and Medicine, King's College, London, UK.

Coastal Carolina Neonatology, Wilmington, NC, USA.

出版信息

Clinicoecon Outcomes Res. 2017 Jan 4;9:49-57. doi: 10.2147/CEOR.S122462. eCollection 2017.

DOI:10.2147/CEOR.S122462
PMID:28115859
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5221546/
Abstract

OBJECTIVE

To human milk fortifier (LHMF) compared to a powdered human milk fortifier (PHMF) in preterm infants in the US from the perspective of third-party payers and parents.

METHODS

This was a decision modelling study using patient data obtained from a randomized controlled trial comparing a LHMF with a PHMF in preterm infants, supplemented with additional data obtained by performing a chart review among 79% of the trial patients. The model estimated the cost-effectiveness of LHMF versus PHMF in US$ at 2014/2015 prices.

RESULTS

More infants in the LHMF group were discharged home (92% versus 89%) and more infants in the PHMF group were transferred to another unit (9% versus 5%). Gestational age was an independent predictor for being discharged home (odds ratio of 2.18; =0.006 for each week of gestational age). Mean length of neonatal intensive care unit (NICU) stay was 1 day less in the LHMF than the PHMF group (62.3 versus 63.4 days), but mean length of NICU stay among infants who developed NEC or sepsis was 79.3 days and 61.2 days in the PHMF and LHMF groups, respectively. Total management cost up to discharge was $10,497 per infant less in the LHMF group than the PHMF group ($240,928 versus $251,425).

CONCLUSION

Using LHMF instead of PHMF in preterm infants enabled resources to be freed-up for alternative use within the system. There is no health economic reason why LHMF should not be used in preference to PHMF in the NICU.

摘要

目的

从第三方支付方和家长的角度,比较美国早产儿使用液体人乳强化剂(LHMF)与粉状人乳强化剂(PHMF)的情况。

方法

这是一项决策建模研究,使用从一项比较LHMF与PHMF对早产儿影响的随机对照试验中获取的患者数据,并补充了对79%的试验患者进行病历审查所获得的额外数据。该模型以2014/2015年的价格估算了LHMF与PHMF的成本效益(以美元计)。

结果

LHMF组中更多婴儿出院回家(92%对89%),PHMF组中更多婴儿转至另一科室(9%对5%)。胎龄是出院回家的独立预测因素(比值比为2.18;胎龄每增加一周,P = 0.006)。LHMF组新生儿重症监护病房(NICU)的平均住院时间比PHMF组少1天(62.3天对63.4天),但发生坏死性小肠结肠炎(NEC)或败血症的婴儿中,PHMF组和LHMF组的NICU平均住院时间分别为79.3天和61.2天。至出院时,LHMF组每名婴儿的总管理成本比PHMF组少10,497美元(240,928美元对251,425美元)。

结论

在早产儿中使用LHMF而非PHMF可在系统内腾出资源用于其他用途。在新生儿重症监护病房(NICU)中,没有健康经济学理由不优先使用LHMF而非PHMF。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e3d/5221546/2057171049f2/ceor-9-049Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e3d/5221546/bde7eaa7e56d/ceor-9-049Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e3d/5221546/0de45d7552e6/ceor-9-049Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e3d/5221546/2057171049f2/ceor-9-049Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e3d/5221546/bde7eaa7e56d/ceor-9-049Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e3d/5221546/0de45d7552e6/ceor-9-049Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e3d/5221546/2057171049f2/ceor-9-049Fig3.jpg

相似文献

1
Relative cost-effectiveness of using a liquid human milk fortifier in preterm infants in the US.在美国,使用液态人乳强化剂对早产儿的相对成本效益。
Clinicoecon Outcomes Res. 2017 Jan 4;9:49-57. doi: 10.2147/CEOR.S122462. eCollection 2017.
2
A new liquid human milk fortifier and linear growth in preterm infants.一种新型液态人乳强化剂与早产儿的线性生长。
Pediatrics. 2012 Oct;130(4):e928-35. doi: 10.1542/peds.2011-3120. Epub 2012 Sep 17.
3
Growth, efficacy, and safety of feeding an iron-fortified human milk fortifier.喂养铁强化人乳强化剂的生长、功效及安全性。
Pediatrics. 2004 Dec;114(6):e699-706. doi: 10.1542/peds.2004-0911. Epub 2004 Nov 15.
4
Growth of Very Low Birth Weight Infants Who Received a Liquid Human Milk Fortifier: A Randomized, Controlled Multicenter Trial.
J Pediatr Gastroenterol Nutr. 2022 Mar 1;74(3):424-430. doi: 10.1097/MPG.0000000000003321.
5
Comparison of the effect of two human milk fortifiers on clinical outcomes in premature infants.两种人乳强化剂对早产儿临床结局影响的比较。
Nutrients. 2014 Jan 3;6(1):261-75. doi: 10.3390/nu6010261.
6
Highly Concentrated Preterm Formula as an Alternative to Powdered Human Milk Fortifier: A Randomized Controlled Trial.高浓缩早产配方奶粉替代母乳强化剂粉剂:一项随机对照试验。
J Pediatr Gastroenterol Nutr. 2017 Nov;65(5):574-578. doi: 10.1097/MPG.0000000000001638.
7
Clinical and nutritional outcomes of two liquid human milk fortifiers for premature infants.两种用于早产儿的液态母乳强化剂的临床和营养结局
J Neonatal Perinatal Med. 2017;10(4):393-401. doi: 10.3233/NPM-16164.
8
Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants.坏死性小肠结肠炎的成本和完全以人乳为基础的产品在喂养极早产儿中的成本效益。
Breastfeed Med. 2012 Feb;7(1):29-37. doi: 10.1089/bfm.2011.0002. Epub 2011 Jun 30.
9
Enhanced growth of preterm infants fed a new powdered human milk fortifier: A randomized, controlled trial.喂养新型粉状母乳强化剂的早产儿生长加速:一项随机对照试验。
Pediatrics. 2000 Sep;106(3):581-8. doi: 10.1542/peds.106.3.581.
10
Liquid human milk fortifier significantly improves docosahexaenoic and arachidonic acid status in preterm infants.液态人乳强化剂可显著改善早产儿的二十二碳六烯酸和花生四烯酸状态。
Prostaglandins Leukot Essent Fatty Acids. 2014 Sep;91(3):97-103. doi: 10.1016/j.plefa.2014.03.002. Epub 2014 Mar 29.

本文引用的文献

1
Decreased cost and improved feeding tolerance in VLBW infants fed an exclusive human milk diet.纯母乳喂养的极低出生体重儿喂养成本降低且喂养耐受性提高。
J Perinatol. 2016 Mar;36(3):216-20. doi: 10.1038/jp.2015.168. Epub 2015 Nov 12.
2
Factor affecting length of stay in late preterm infants: an US national database study.影响晚期早产儿住院时间的因素:一项美国国家数据库研究。
J Matern Fetal Neonatal Med. 2015 Mar;28(5):598-604. doi: 10.3109/14767058.2014.927428. Epub 2014 Jun 20.
3
Economic benefits and costs of human milk feedings: a strategy to reduce the risk of prematurity-related morbidities in very-low-birth-weight infants.
母乳喂养的经济效益与成本:降低极低出生体重儿早产相关疾病风险的策略。
Adv Nutr. 2014 Mar 1;5(2):207-12. doi: 10.3945/an.113.004788.
4
Update of adjustable fortification regimen for preterm infants: a new protocol.早产儿可调节强化方案更新:一项新方案。
J Biol Regul Homeost Agents. 2012 Jul-Sep;26(3 Suppl):65-7.
5
A new liquid human milk fortifier and linear growth in preterm infants.一种新型液态人乳强化剂与早产儿的线性生长。
Pediatrics. 2012 Oct;130(4):e928-35. doi: 10.1542/peds.2011-3120. Epub 2012 Sep 17.
6
Cost of morbidities in very low birth weight infants.极低出生体重儿的并发症成本。
J Pediatr. 2013 Feb;162(2):243-49.e1. doi: 10.1016/j.jpeds.2012.07.013. Epub 2012 Aug 19.
7
Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants.坏死性小肠结肠炎的成本和完全以人乳为基础的产品在喂养极早产儿中的成本效益。
Breastfeed Med. 2012 Feb;7(1):29-37. doi: 10.1089/bfm.2011.0002. Epub 2011 Jun 30.
8
An exclusively human milk-based diet is associated with a lower rate of necrotizing enterocolitis than a diet of human milk and bovine milk-based products.单纯人乳喂养的婴儿患坏死性小肠结肠炎的比率低于人乳加牛乳及牛乳制品喂养的婴儿。
J Pediatr. 2010 Apr;156(4):562-7.e1. doi: 10.1016/j.jpeds.2009.10.040. Epub 2009 Dec 29.
9
Adjustable fortification of human milk fed to preterm infants: does it make a difference?对早产儿喂养的母乳进行可调节强化:这有区别吗?
J Perinatol. 2006 Oct;26(10):614-21. doi: 10.1038/sj.jp.7211571. Epub 2006 Aug 3.
10
Estimates of the cost and length of stay changes that can be attributed to one-week increases in gestational age for premature infants.对早产儿胎龄每增加一周所导致的费用和住院时间变化的估计。
Early Hum Dev. 2006 Feb;82(2):85-95. doi: 10.1016/j.earlhumdev.2006.01.001. Epub 2006 Feb 3.